publications

Rocha L, Ackerman RF, Nassir Y, Chugani HT, Engel J. “Characterization of My Opioid Receptor Binding During Amygdala Kindling in Rats and Effects of Chronic Naloxone Pre-Treatment: and Autoradiographic Study.” Epilepsy Research 14:195-208, 1993.

Nassir Y, Regunathan S, Reis DJ, Vaughan ED Jr, Felsen D. “Castration of Rats Upregulates the Imidazoline Receptor in Prostate.” Ann NY Acad Sci 763:174177. 1995.

Rugunathan S, Nassir Y, Sundaram K, Vaughan ED Jr, Reis DJ, Felsen D. “Expression of I Imidazoline Receptor in Rat Prostate and Regulation by Testosterone.” J BioChem Pharmacol (Submitted), 1999

Berenson JR, Yang HH, Vescio RA, Nassir Y, Mapes R, Lee S-P, Wilson J, Yellin O, Morrison B, Hilger J, and Swift RA, “Safety and Efficacy of Bortezomib and Melphalan Combination in Patients with Relapsed or Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study After Longer Follow-up,” Annals of Hematology, 87:623-631 (2008)

Berenson JR, Yellin O, Woytowitz D, Flam MS, Cartmell A, Patel R, Duvivier H, Nassir Y, Eades B, Abaya CD, Hilger J, and Swift RA, “Bortezomib, Ascorbic Acid and Melphalan (BAM) Therapy for Patients with Newly Diagnosed Multiple Myeloma: and Effective and Well-tolerated Frontline Regimen,” Eur J Haematol, 82:432-439 (2009)

James R Berenson, Ori Yellin, Alan Carmell, Thomas Woliver, Marshall Flam, Youram Nassir, Robert Vescio, and Regina a Swift, “A Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients with Relapsed /Refractory (R/R) Multiple Myeloma (MM),” American Society of Hematology Annual Meeting, 116:4936 (November 2010)

Berenson JR, Yellin O, Kazamel T, Hilger JD, Chen CS, Cartmell A, Woliver T, Flam M, Bravin E, Nassir Y, Vescio R, and Swift RA, “A Phase 2 Study of Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Patients with Relapsed/Refractory Multiple Myeloma,” Leukemia, 26(7):1675-80 (2012).

Berenson JR, Yellin O, Shamasunder HK, Chen CS, Charu V, Woliver TB, Sanani S, Shlutz M, Nassir Y, Swift RA, Andreu-Vieyra C, and Vescio R, “A Phase 3 Trial of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients with Multiple Myeloma,” Supportive Care Cancer (2015) 23:1503–1512

Kunchandy J, Chugani MT, Nassir Y. “Hemidecortication in Rat Pups: Effects on Local Cerebral Metabolic Rates for Glucose in Adulthood”. Ann Neurol 28A12, 1990.

Tatsukawa K, Chugani NT, Brown O, Nassir Y. “Chronic Cerebral Glucose Metabolic Rates in Hemidecorticated Rats are Dependent on Age-at-Lesion J Cerebral Blood Flow and Metabolism” 11 (2):S794, 1991.

Rocha L, Engel J Jr, Nassir Y, Chugani HT. “Effects of Upregulation of Opioid Receptors on Amygdaloid Kindling in Rats and its Association with Mu Opioid Receptor Levels.” Epilepia 32(1):33, 1991.

Nassir Y, Tatsukawa K, Villablanca J, Chugani NT. Increased 3H-Flunitrazepam Binding in Visual Structures of Adult Cerebral Hemispherectomized Compared to Neonatal

Yellin O, Crowley J, Swift R, Duvivier H, Nassir Y and Berenson J, “Factors that Determine Overall Survival Among Patients with Multiple Myeloma Treated with Zoledronic Acid,” Clin Exp Metastasis, Proceedings of Skeletal Complications of Malignancy V, Philadelphia, PA 25 Suppl:2008: Abstract # S32:29 (October 25-27, 2007)

Berenson JR, Yellin O, Woytowitz D, Flam MS, Cartmell A, Patel R, Duvivier H, Nassir Y, and Swift RA, “Bortezomib, Ascorbic Acid and Melphalan (BAM) Therapy for Patients (pts) with Newly Diagnosed Multiple Myeloma (MM): An Effective and Well-Tolerated Frontline  Regimen,” 2007 American Society of Hematology (ASH) Meeting Abstracts, Blood, Part I, Vol110, Issue 11, Abstract # 3602 (11/2007)

Berenson JR, Yellin O, Boccia RV, Flam MS, Wong S-F, Batuman O, Moezi MM, Woytowitz D, Duvivier H, Nassir Y, and Swift RA, “Zoledronic Acid (ZOL) Markedly Improves Bone Mineral Density (BMD) for Patients (PTS.) with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Bone Loss,” 2007 American Society of  Hematology (ASH) Meeting Abstracts, Blood, Part I, Vol. 110, Issue 11, Abstract# 3606 (11/ 2007).

Berenson JR, Yellon O, Crowley J, Duvivier H, Nassir Y, and Swift RA, “Factors that Determine Overall Survival among Patients (Pts) with Multiple Myeloma (MM( Treated with Zoledronic Acid (ZOL): Lack of Skeletal-Related Events (SREs) and Occurrence of Osteonecrosis of the Jaw (ONJ) Predict Improved Survival,” 2007 American Society of Hematology (ASH) Meeting Abstracts, Blood, Part I, Vol. 110, Issue 11, Abstract # 4842 (11/2007)

Berenson JR, Yellon O, Crowley J, Duvivier H, Nassir Youram, and Swift RA, “Factors that

Berenson JR, Yellin O, Boccia RV, Flam MS, Wong S-F, Bautman O, Moexi MM, Woytowitz D, Duvivier H, Nassir Youram, and Swift RA, “Zoledronic Acid (ZOL) Markedly Improves Bone Mineral Density (BMD) for Patients (Pts) with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Bone Loss.” American Society of Hematology 49th Annual Meeting, Abstract $# 956660, 2007

Berenson JR, Yellin O, Woytowitz D, Flam MS, Cartmell A, Patel R, Duvivier H, Nassir Youram, and Swift RA, “Bortezomib, Ascorbic Acid and Melphalan (BAM) Therapy for Patients (Pts) with Newly Diagnosed Multiple Myeloma (MM): An Effective and Well tolerated Frontline Regimen.” American Society of Hematology 49th Annual Meeting, Abstract # 956738, 2007

Berenson JR, Yang HH, Vescio RA, Nassir Youram, Mapes R, Lee S-P, Wilson J, Yellin O,

Berenson JR, Yellin O, Boccia RV, Flam MS, Wong S, Batuman O, Moezi MM, Woytowitz DV, Duvivier HL, Nassir Youram, and Swift R, “Marked improvement in bone mineral density (BMD) for patients (pts.) with monoclonal Gammopathy of undetermined significance (MGUS) using Zoledronic acid (ZOL), J Clin Onol 26: 2008 (May 20 supplement; abstract 8550)

Berenson JR, Yellin O, Crowley J, Makary A, Gravenor DS, Yang HH, Upadhyaya GH, Flinn IW, Staszewski H, Tiffany NM, Sanani S, Farber CM, Morganstein N, Duvivier H, Nassir Youram, Sefardi A, Shamouelian A, and Swift RA. “Overall Survival Among Patients with Multiple Myeloma (MM) Treated with Zoledronic Acid (ZOL).” XII International Myelom Workshop, Washington, DC, Clin Lymph & Myeloma, 9: Abstract 088 (February 2009)

Berenson JR, Yellin O, Patel R, Duvivier H, Nassir Youram, Mapes R, Abaya CD, and Swift RA, “A Phase I Study of Samarium Lexidronam/Bortezomib Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma,” Clin Cancer Res, 15(3):1069-1075 (2009)

Berenson JR, Yellin O, Boccia RV, Nassir Youram, Rothstein S, and Swift R, “A Phase I Study of Oral Melphalan Combined with LBH589 for Patients with Relapsed or Refractory Multiple Myeloma (MM),” 2009 American Society of Hematology Annual Meeting Abstracts 114(22): Abstract # 1855:736 (December 2009)

Berenson JR, Donahue DB, Yellin O, Upadhyaya G, Nassir Youram, Swift RA, “A Randomized Trial Evaluating a New Powered Bone Marrow Aspirate and Core Biopsy System Compared to Traditional Manual Devices,” 2009 American Society of Hematology Annual Meeting Abstracts, 114(22): Abstract # 4234 (December 2009)

Berenson JR, Yellin O, Patel R, Chen C-S, Boccia RV, Colbourn D, Yang H, Gupta V, Geils GF,

Berenson JR, Yellin O, Cartmell A, Woliver T, Flam M, Nassir Youram, Vescio R, and Swift RA, “A Phase II Study of Pegylated Liposomal Doxorubicin (PLD), “Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients with Relapsed/Refractory (R/R) Multiple Myeloma (MM),” American Society of Hematology Annual Meeting, Blood 116:4936 (November 2010).

Ori Yellin1, James R. Berenson1, 2, 3, Ralph V. Boccia4, Allen Cohn5, Paul Berard6, Hassan

Berenson J, Yellin O, Kazamel T, Boccia R, Matous J, Dressler K, Nassir Youram, Rothstein S, and Swift, R, “A Phase I/II Study of Oral Melphalan (MEL) Combined with Panobinostat (PAN) for Patients with Relapsed or Refractory (R/R) Multiple Myeloma (MM),” International Myeloma Workshop (submitted for the 2011 meeting).

Berenson J, Yellin O, Kazamel T, Cartmell A, Woliver T, Flam M, Nassir Youram, Vescio R, and Swift R, “A Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib,

Yellin O, Berenson JR, Kazamel T, Chen C-S, Cartmell A, Woliver T, Flam M, Bravin E, Nassir, Youram, Vescio R, and Swift RA, “A Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients with Relapsed/Refractory (R/R) Multiple Myeloma (MM),” J Clin Oncology, presented at ASCO meeting, 29:524s, abstract #8082 (June, 2011).

Kazamel T, Berenson JR, Yellin O, Boccia RV, Matous J, Dressler KA, Nassir Youram,

Berenson J, Yellin O, Boccia R, Matous J, Dressler K, Jamshed, Kingsley, Harb, Noga, Nassir Youram, and Swift R, “A Phase 1/2 Trial of Melphalan (MEL) Combined with Panobinostat (PAN) for Patients with Relapsed or Refractory (R/R) Multiple Myeloma (MM),” J Clin Oncology, submitted for ASCO meeting 2012.

Berenson J, Yellin O, Dichmann R, Patel-Donnelly D, Boccia R, Hilger J, Nassir Youram, Swift R, and Vescio R, “A Phase I/II Study of Carfilzomib as a Replacement for Bortezomib for Multiple Myeloma Patients Progressing While Receiving a Bortezomib-Containing Combination Regimen,” J Clin Oncology, abstract #8098 submitted for ASCO meeting 2012.

Berenson JR, Hilger J, Klein L, Eshaghian S, Nassir Youram, Swift R, and Vescio R, “A Phase 1⁄2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin in Patients with Relapsed/Refractory Multiple Myeloma,” American Society of Hematology (ASH Annual Meeting Abstracts) Blood 120 Abstract 2979 (November 2012).

Berenson JR, Hilger J, Dischmann R, Patel-Donnelly D, Boccia R, Bessudo A, Stampleman L, Gravenor D, Eshaghian S, Nassir Youram, Swift R, and Vescio R, “A Phase I/II Study of

Berenson JR, Hilger J, Dichman R, Patel-Donnelly D, Boccia R, Bessudo A, Stampleman L,

Hilger J, Berenson JR, Klein L, Bessudo A, Rosen P, Eshaghian S, Chamras H, Nassir Youram, Swift R, and Vescio R, “A Phase I/II Study of Pomalidomide (POM), Dexamethasone (DEX) and Pegylated Liposomal Doxorubicin (PLD) for Patients with Relapsed/Refractory (R/R) Multiple Myeloma (MM),” J Clin Oncol 31, 2013 (suppl; abstr 8598)

Berenson JR, Yellin O, Kazamel T, Hilger JD, Chen CS, Cartmell A, Woliver T, Flam M, Bravin E, Nassir Youram, Vescio R, and Swift RA, “A Phase 2 study of pegylated liposomal doxorubicin, Bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma,” Leukemia, 26(7): 1675-80 (2012).

Berenson JR, Klein L, Rosen P, Woliver T, Eshaghian S, Nassir Youram, Swift RA, and Vescio R, “Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin For Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1/2 Trial,” American Society of Hematology (ASH Annual Meeting Abstracts) Blood 122(21):3218 (November 2013).

Berenson JR, Klein L, Rosen P, Woliver T, Eshaghian S, Nassir Youram, Swift RA, and Vescio R, “A Phase I/II Study of Pomalidomide (POM), Dexamethasone (DEX) and Pegylated Liposomal Doxorubicin (PLD) for Patients with Relapsed/Refractory Multiple Myeloma (RRMM),” J Clin Oncol 32, 2014 (suppl; abstr e19586^).

Berenson JR, Klein L, Rosen P, Woliver T, Eshaghian S, Nassir Youram, Swift RA, and Vescio R, “A Phase I/II Study of Pomalidomide (POM), Dexamethasone (DEX) and Pegylated Liposomal Doxorubicin (PLD) for Patients with Relapsed/Refractory Multiple Myeloma (RRMM),” J Clin Oncol 32, 2014 (suppl; abstr e19586^).

Lepor, Norman E., Nassir Youram, “Evaluation of Long-term Cardiovascular Effects”, Reviews in Cardiovascular Medicine, 15 (1) 2014.

Berenson JR, Stampleman, Bessudo A, Rosen PJ, Klein LM, Woliver T, Flam MS, Eshaghian S, Nassir Youram, Swift RA, and Vescio R, “A Phase 1 /2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma,” Blood 124(21):3469 (December 2014).

Berenson J, Stampleman L, Bessudo A, Rose PJ, Klein L, Woliver T, Flam M, Eshaghian S,

Berenson A, Vardanyan S, David M, Wang J, Harutyunyan NM, Gottlieb J, Halleluyan R, Spektor TM, Udd KA, Eshaghian S, Nassir Youram, Eades B, Swift R, and Berenson JR, “Improved Clinical Outcomes for Multiple Myeloma Patients Treated at a Single Specialty Clinic,” Annals of Hematol. 96:441-448 (2017).

Berenson A, Vardanyan S, David M, Wang J, Harutyunyan NM, Gottlieb J, Halleluyan R, Spektor TM, Udd KA, Eshaghian S, Nassir Youram, Eades B, Swift R, and Berenson JR, “Outcomes of Multiple Myeloma Patients Receiving Bortezomib, Lenalidomide and Carfilzomib,” Annals of Hematol. 96:449-459 (2017).

Vidisheva AP, Wang J, Spektor TM, Bitran JD, Lutzky J, Tabbara IA, Ye JZ, Ailawadhi S,

Cohen A, Spektor TM, Stampleman, Bessudo A, Rosen PJ, Klein LM, Woliver T, Flam M,

Berenson JR, To J, Spektor TM, Martinez D, Sanchez A, Ghermezi M, Turner C, Swift A, Eades B, Schwartz G, Eshaghian S, Stampleman L, Moss R, Nassir Youram, Patel R, Bessudo A, Lim S, Vescio R. “A Phase 1 Trial of Ruxolitinib, Lenalidomide, and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM),” American Society of Clinical Oncology Annual Meeting. June 2019. Chicago, IL.

Berenson JR, To J, Spektor T, Martinez D, Sanchez A, Ghermezi M, Turner C, Swift R, Eades B, Schwartz G, Eshaghian S, Stampleman L, Moss R, Nassir Youram, Patel R, Bessudo A, Lim S, Vescio R. “A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM),” 17th International Myeloma Workshop. September 2019 (submitted)

Berenson JR, To J, Spektor TM, Martinez D, Sanchez A, Ghermezi M, Turner C, Swift A, Eades B, Schwartz G, Eshaghian S, Stampleman L, Moss R, Nassir Youram, Patel R, Bessudo A, Lim S, and Vescio R. “A Phase 1 Trial of Ruxolitinib, Lenalidomide, and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM),” J Clin Oncol 37, 2019 (suppl: abstr 8048).

Berenson JR, To J, Spektor TM, Martinez D, Sanchez A, Ghermezi M, Turner C, Swift R, Eades B, Schwartz G, Eshaghian S, Stampleman L, Moss RA, Nassir Youram, Patel R, Bessudo A, Greenwald D, Boccia R, Lim S, and Vescio R. “A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM),” Blood . 134 (Supplement 1):1903 (2019).

Chen H, Li M, Sanchez E, Ng N, Yu E, Bujarski S, Yin Z, Hekmati T, Field D, Wang J, Nassir

Xu N, Li M, Sanchez E, Ng N, Yu E, Bujarski S, Yin Z, Hekmati T, Field D, Wang J, Nassir

Chen H, Li M, Sanchez E, Ng N, Yu E, Bujarski S, Yin Z, Hekmati T, Field D, Wang J, Nassir